Articles

Dermatologic adverse events are frequently reported in patients treated with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), dual EGFR/human epidermal growth factor receptor 2 (HER2) blockers, and ErbB family blockers. Read More ›

Panelists at the 2013 Annual Conference of the National Comprehensive Cancer Network (NCCN) view the oncology world as rapidly changing, and the impact of this—for better or for worse—will be felt by healthcare providers, payers, and patients alike. Read More ›

Cancer anorexia-cachexia syndrome (CACS) is underrecognized and underreported in patients with advanced lung cancer receiving routine clinical care. Read More ›

Longer-Term Analysis of Pivotal Trial Confirms Safety and Efficacy Read More ›

Promising results were obtained with enzalutamide monotherapy in patients with hormone-naive prostate cancer. Read More ›

Data continue to build for the use of immunotherapy in the treatment of patients with metastatic melanoma. Read More ›

In this issue of Conquering the Cancer Care Continuum you will learn about a hot topic that most cancer centers and oncologists are struggling to make a reality: survivorship care plans for all cancer survivors at the end of (acute) treatment, coupled with a comprehensive treatment summary. There is good news and bad news to share with you about the need for this document. Read More ›

Cancer remains the second leading cause of death in the United States, and the American Cancer Society estimates there are approximately 13.7 million cancer survivors in the United States, with 18 million projected by 2022. Read More ›